Introduction to Received Intravitreal Methotrexate

Sentence Examples

Learn more from Received Intravitreal Methotrexate

Received Intravitreal Methotrexate sentence examples

10.4103/ijo.IJO_1697_19

The patient received intravitreal methotrexate 400 μg/0.

Neoplastic lymphomatous submaculopathy

10.1186/s12885-019-5530-7

Additionally, the left eye received intravitreal methotrexate (MTX) (weekly for the first month, every two weeks for the second month, and monthly thereafter) over a course of twelve months.

Bilateral mantle cell lymphoma of the ciliary body that responded to a combined local radiotherapy and chemotherapy regimen: a case report

Learn more from Received Intravitreal Methotrexate

An Overview of Received Intravitreal Methotrexate

Received Intravitreal Methotrexate
Encyclopedia

What is/are Intravitreal Methotrexate?

Intravitreal Methotrexate - Each were treated with intravitreal methotrexate injections. [1] Three subsequent treatments with intravitreal methotrexate led to regression of the VRL. [2] To assess the effects of weekly post-operative intravitreal methotrexate injections on eyes with grade C proliferative vitreoretinopathy (PVR) that underwent surgical repair. [3] Optimal treatment for PVRL is not defined given its relatively low incidence but often requires a combination of systemic and/or intravitreal methotrexate and rituximab. [4] BACKGROUND/PURPOSE To investigate the clinical characteristics of intraocular lymphoma and to evaluate two protocols of intravitreal methotrexate injection. [5] Objective The objective of this pilot study was to evaluate the efficacy and safety of per-operative intravitreal methotrexate (MTX) infusion during vitrectomy in patients of retinal detachment (RD) with advanced grade proliferative vitreoretinopathy (PVR). [6] Patients received local and systemic therapies: intravitreal methotrexate (MTX, 400 μg, 0. [7] He was treated with multiple injections of intravitreal Methotrexate 400µg/0. [8] Herein we present anterior segment optical coherence tomography findings in a 21-years-old, male, diffuse B-cell Acute Lymphoblastic Leukemia (ALL) patient who has a leukemic iris infiltration in his left eye that was successfully treated with intravitreal methotrexate. [9] PURPOSE The purpose of this study was to evaluate the corneal toxicity of intravitreal methotrexate used for the prevention of proliferative vitreoretinopathy (PVR). [10] He sustained complete right vision loss due to right optic nerve invasion by the tumor, leading to prophylactic intravitreal methotrexate to the contralateral eye. [11] The patient was treated with intravitreal methotrexate with initial success, but eventual failure after 10 months. [12] The patient received intravitreal methotrexate 400 μg/0. [13] A subsequent relapse occurred that responded rapidly to intravitreal methotrexate in the absence of antiviral/antibiotics. [14] The patient was treated with pars plana vitrectomy as well as systemic chemotherapy, intrathecal methotrexate, intravitreal methotrexate, and intravitreal rituximab with good post-operative outcomes. [15] Additionally, the left eye received intravitreal methotrexate (MTX) (weekly for the first month, every two weeks for the second month, and monthly thereafter) over a course of twelve months. [16] Materials and methods A retrospective review was performed on a cohort of five consecutive eyes with severe PVR and recurrent retinal detachment that were treated with relaxing retinectomy, extended perfluorocarbon liquid tamponade (4–5 weeks) and a series of intravitreal methotrexate (MTX) injections (100–200 µg/0. [17] ABSTRACT Purpose To present a case of necrotizing retinitis with Epstein–Barr virus (EBV)-positive ocular fluid in a patient with sudden unilateral vision loss, which was successfully treated with intravitreal methotrexate (MTX) injections. [18] Results: The patient was treated with serial intravitreal methotrexate injections and subsequently developed a BRAO immediately following her seventh injection. [19]

Received Intravitreal Methotrexate

The patient received intravitreal methotrexate 400 μg/0. [1] Additionally, the left eye received intravitreal methotrexate (MTX) (weekly for the first month, every two weeks for the second month, and monthly thereafter) over a course of twelve months. [2]

Operative Intravitreal Methotrexate

To assess the effects of weekly post-operative intravitreal methotrexate injections on eyes with grade C proliferative vitreoretinopathy (PVR) that underwent surgical repair. [1] Objective The objective of this pilot study was to evaluate the efficacy and safety of per-operative intravitreal methotrexate (MTX) infusion during vitrectomy in patients of retinal detachment (RD) with advanced grade proliferative vitreoretinopathy (PVR). [2]

intravitreal methotrexate injection

Each were treated with intravitreal methotrexate injections. [1] To assess the effects of weekly post-operative intravitreal methotrexate injections on eyes with grade C proliferative vitreoretinopathy (PVR) that underwent surgical repair. [2] BACKGROUND/PURPOSE To investigate the clinical characteristics of intraocular lymphoma and to evaluate two protocols of intravitreal methotrexate injection. [3] Results: The patient was treated with serial intravitreal methotrexate injections and subsequently developed a BRAO immediately following her seventh injection. [4]